Neoadjuvant epirubicin, oxaliplatin and capecitabine (EOX) in locally advanced resectable gastroesophageal junction and gastric adenocarcinoma: the...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Martínez
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors J. Martínez1, M. Limón2, I. Sánchez3, A. Falcón3
  • 1Virgen del Rocio Hospital, Seville, Spain, /
  • 2H.U.V. del Rocío, Sevilla, Spain, /
  • 3Hospital Virgen del Rocío, Sevilla, Spain, /

Abstract

A regimen of perioperative epirubicin, cisplatin and infused fluorouracil (EFC) improves survival among patients with resectable gastroesophageal cancer. In the metastatic setting, the combination of epirubicin, oxaliplatin and capecitabine (EOX) is at least as effective as ECF. We assessed the efficacy of neoadjuvant EOX in patients with resectable gastroesophageal junction (GEJ) and gastric adenocarcinoma.